{{Drugbox
| IUPAC_name        = (1a''R'',2''S'',5''R'',5a''S'',6S,8a''S'',9''R'',10a''R'')-5,5a-Dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1''H''-2,8a-methanocyclopenta[''a'']cyclpropa[''e''][10]annulen-6-yl (2''Z'')-2-methylbut-2-enoate
| image             = Ingenol 3-angelate.svg
| alt               = 
| caption           =

<!-- Clinical data -->
| tradename         = Picato
| Drugs.com         = {{Drugs.com|parent|picato}}
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = C
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status      = 
| routes_of_administration = Topical (gel)

<!-- Pharmacokinetic data -->
| bioavailability   = Below detection level
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         =

<!-- Identifiers -->
| CAS_number        = 75567-37-2
| ATCvet            = 
| ATC_prefix        = D06
| ATC_suffix        = BX02
| PubChem           = 6918670
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 66913
| DrugBank          = 
| ChemSpiderID      = 26325194
| synonyms          = PEP005, ingenol-3-angelate

<!-- Chemical data -->
| C=25 | H=34 | O=6
| molecular_weight  = 430.534 g/mol
| StdInChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1
| StdInChIKey = VDJHFHXMUKFKET-WDUFCVPESA-N
| smiles = C/C=C(/C)\C(=O)O[C@H]1C(C)=C[C@]23[C@]1(O)[C@H](O)C(CO)=C[C@H](C3=O)[C@H]4[C@H](C4(C)C)C[C@H]2C
}}
'''Ingenol mebutate''' ('''ingenol-3-angelate''', '''PEP005''', [[LEO Pharma]] trade name '''Picato''') is a substance found in the sap of the plant ''[[Euphorbia peplus]]''<ref name=Fallen /> and an inducer of cell death. A gel formulation of the drug has been approved by the U.S. [[Food and Drug Administration]] (FDA)<ref name="Drugs@FDA" /> and by the [[European Medicines Agency]] (EMA)<ref name="EMA" /> for the topical treatment of [[actinic keratosis]]. Two different strengths of the gel are approved for use on either the face and scalp (0.015%) or the trunk and extremities (0.05%), respectively.<ref name="Approved label" />

Results from four multicenter, randomized, double-blind studies have shown that ingenol mebutate gel applied topically for 2 to 3 days is effective for field treatment of actinic keratoses.<ref name=Lebwohl />

==Adverse effects==
Irritations of the application site are very common. This includes redness, scaling, crusting, pain, pruritus, and sometimes infection. Other side effects include eye irritation such as [[periorbital edema]] (3% of patients in studies), headache (2%) and [[nasopharyngitis]] (running nose, 2%).<ref name="SFX" />

Allergic reactions or [[shingles]] may also occur.<ref>{{cite web|title=Picato (ingenol mebutate) Gel: Drug Safety Communication - FDA Warns of Severe Adverse Events, Requires Label Changes|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm459311.htm|accessdate=24 August 2015|date=2015-08-21}}</ref>

==Interactions==
As ingenol mebutate is practically not absorbed through the skin, interactions with oral drugs are unlikely.<ref name="Drugs.com" /><ref name="AustriaCodex" />

==Chemistry==
The substance is an [[ester]] of the [[diterpene]] ingenol and [[angelic acid]].  A 3-step semisynthesis of ingenol mebutate starting from ingenol was described.<ref>Liang, X.; Grue-Sørensen, G.; Petersen, A. K.; Högberg, T. (2012), "Semisynthesis of Ingenol 3-Angelate (PEP005): Efficient Stereoconservative
Angeloylation of Alcohols", ''SYNLETT'' (23): 2647–2652. https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0032-1317415.pdf</ref> A 14-step synthesis of (+)-ingenol from [[Carene|(+)-3-carene]], which is a relatively inexpensive constituent of [[turpentine]], was published in July 2013.<ref name=synthesis>{{Cite journal | last1 = Jorgensen | first1 = L. | last2 = McKerrall | first2 = S. J. | last3 = Kuttruff | first3 = C. A. | last4 = Ungeheuer | first4 = F. | last5 = Felding | first5 = J. | last6 = Baran | first6 = P. S. | authorlink6 = Phil S. Baran| title = 14-Step Synthesis of (+)-Ingenol from (+)-3-Carene | doi = 10.1126/science.1241606 | journal = Science | volume = 341 | issue = 6148 | pages = 878–882 | year = 2013 | pmid =  23907534| pmc = }}</ref>

==Research==
Ingenol mebutate has also been found to be useful for reactivating latent [[HIV]] virus in cells taken from individuals who have tested negative for signs of the disease following extended courses of anti-retroviral drugs, raising the possibility that this drug may be used to expose the last traces of virus, and thus potentially provide a permanent cure for HIV infection. Research is ongoing to determine whether the effects observed ''in vitro'' are also seen in animal models, with a view to eventual human trials for this application.<ref>{{cite journal | vauthors = Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, Cai I ''et al'' | year = 2015 | title = Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation | url = | journal = PLoS Pathogens | volume = 11 | issue = 7| page = e1005066 | doi = 10.1371/journal.ppat.1005066 }}</ref>

==See also==
* [[Thapsigargin]]
* [[Tigilanol tiglate]]

==References==
{{reflist|2|refs=
<ref name=Fallen>{{cite journal | journal = Skin Therapy Lett | year = 2012  | volume = 17 | issue = 2 | pages = 1–3 | title = Ingenol mebutate: An introduction |vauthors=Fallen RS, Gooderham M | pmid = 22358305 | url = http://www.skintherapyletter.com/2012/17.2/1.html}}</ref>
<ref name="Drugs@FDA">[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=202833&DrugName=PICATO&ActiveIngred=INGENOL%20MEBUTATE&SponsorApplicant=LEO%20PHARMA%20AS&ProductMktStatus=1&goto=Search.DrugDetails Picato Drug Details at Drugs@FDA]</ref>
<ref name="EMA">[http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002275/human_med_001600.jsp&mid=WC0b01ac058001d124 European Public Assessment Report (EPAR) for Picato]</ref>
<ref name="Approved label">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202833lbl.pdf Picato® Gel label at Drugs@FDA]</ref>
<ref name=Lebwohl>{{cite journal | journal = N Engl J Med | year = 2012  | volume =  366| issue = 11 | pages = 1010–1019 | title = Ingenol Mebutate Gel for Actinic Keratosis |vauthors=Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B | pmid = 22417254 | doi = 10.1056/NEJMoa1111170}}</ref>
<ref name="SFX">Drugs.com: [http://www.drugs.com/sfx/picato-side-effects.html Picato Side Effects in Detail]</ref>
<ref name="Drugs.com">Picato {{Drugs.com|pro|picato}}</ref>
<ref name="AustriaCodex">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2013|language=German}}</ref>
}}

{{Antibiotics and chemotherapeutics for dermatological use}}

[[Category:Dermatologic drugs]]
[[Category:Antineoplastic drugs]]
[[Category:Diterpenes]]
[[Category:Cyclopropanes]]